Abstract
The article describes some epidemiological data on COPD and pathogenetic nature of the disease. It is an inflammatory response to inhaled gases and particles, the main cells involved in it are neutrophils, macrophages and CD8 lymphocytes.
We also describe the effect of cAMP, which suppresses the activity of immunocytes and inflammatory cells, has the bronchodilator effect on airways and modulates pulmonary nerve activity. Finally, we describe an anti‑inflammatory effect of phosphodiesterase inhibitors and their use in the treatment of COPD.
Results of studies with a selective inhibitor of phosphodiesterase 4, roflumilast, showed a positive effect on the course of COPD. Roflumilast is intended for maintenance treatment of severe COPD (postbronchodilator FEV1 <50%) associated with chronic bronchitis in adults with a history of frequent exacerbations, extending the range of bronchodilator therapy.